Microneedle manufacturing method

Optimized cleaning of microneedles using a methanol-water mixture addresses inefficiencies in impurity removal, enhancing safety and productivity by significantly reducing residual monomers and polymers.

JP2024168788AInactive Publication Date: 2024-12-05KANAGAWA INST OF IND SCI & TECH +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023085727
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing microneedle manufacturing methods face inefficiencies in cleaning impurities, particularly unreacted monomers and unpolymerized polymers, which are not fully removed, posing safety risks for living organisms and impacting productivity.

Method used

A method involving the use of a mixed solution of methanol and water for cleaning microneedles, optimizing the cleaning process by adjusting immersion times and frequency of solution changes to ensure safety and efficiency.

Benefits of technology

The method effectively reduces unreacted monomers and unpolymerized polymers to safe levels, ensuring the safety and productivity of microneedle production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024168788000001_ABST
    Figure 2024168788000001_ABST
Patent Text Reader

Abstract

To optimize washing of a microneedle removed from a mold while safety in an organism is secured.SOLUTION: A manufacturing method of a microneedle 110 has steps for: preparing a mold where a cavity corresponding to a structure of the microneedle 110 is formed; adjusting a pregel solution containing a monomer mixture; injecting the pregel solution in a prescribed part of the mold; polymerizing the monomer mixture in the pregel solution inside the mold to form a pregel composition; removing an obtained molded body from the mold; washing the molded body removed from the mold; and drying the washed molded body. The step for washing the molded body includes impregnating the molded object with a mixed solution of methanol and water.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing a microneedle. [Background technology]

[0002] Microneedles are known as devices for transdermally administering drugs. As disclosed in Patent Document 1, for example, microneedles are provided as patches in which a plurality of needles, each having a length of 1 mm or less and carrying a drug to be administered, are arranged in an array on a flat base, and are configured to deliver drugs via the needles by attaching the patch to the skin surface. Therefore, microneedles have the characteristic of being able to administer drugs continuously for a long period of time in a minimally invasive manner.

[0003] Patent Document 1 also discloses a method for manufacturing microneedles by a micromolding technique using a mold. The method includes the steps of preparing a mold in which a cavity corresponding to a base portion and a needle is formed, injecting a pre-gel solution containing a monomer mixture into the cavity portion of the mold corresponding to the needle, polymerizing the monomer mixture in the pre-gel solution to form a gel composition, forming a base portion integrally with the gel composition in the mold containing the gel composition, and removing the microneedle, which is the molded body obtained by this, from the mold.

[0004] The microneedle disclosed in Patent Document 1 is primarily intended to deliver insulin for the treatment of diabetes, among other drugs, and the monomer mixture contains a phenylboronic acid (PBA) monomer capable of reversibly binding to glucose. By incorporating insulin into a gel composition obtained by polymerization of the monomer mixture, the release of insulin from the gel composition is controlled according to the glucose concentration.

[0005] Here, even if the gel composition such as the monomer concentration and crosslinking density is optimized in the process of forming the gel composition, polymerization does not occur with a 100% probability, so that the microneedle taken out of the mold contains unreacted monomers and polymers that have not been polymerized (in this specification, these monomers and polymers that have not been polymerized are collectively referred to as "impurities"). Therefore, in order to remove these impurities, the microneedle is washed after being taken out of the mold. A washing solution that is a mixed solution of methanol and water is used as the washing solution for washing the microneedle. Since the boronic acid monomer in the gel composition is eluted into the mixed solution by washing, the washing period is set to, for example, 5 to 7 days until the pH of the washing solution becomes 6.4 or higher. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] International Publication No. 2019 / 182099 Summary of the Invention [Problem to be solved by the invention]

[0007] As described above, the pH of the cleaning solution was used as an index of cleaning effect in the past. However, since microneedles are directly applied to living organisms, it is important that safety in living organisms is ensured. In addition, in order to improve the productivity of microneedles, it is also important to perform cleaning efficiently. Therefore, one of the objects of the present invention is to optimize the cleaning of microneedles removed from a mold while ensuring safety in living organisms. [Means for solving the problem]

[0008] According to one aspect of the present invention, there is provided a method for producing a microneedle, comprising the steps of: A step of preparing a mold in which a cavity corresponding to the base portion and the needle portion of the microneedle having a base portion and at least one needle portion integrally provided on the base portion is formed; preparing a pre-gel solution comprising a monomer mixture; injecting the pre-gel solution into at least a portion of the cavity of the mold corresponding to the needle; polymerizing the monomer mixture in the pre-gel solution in the mold to form a gel composition; removing the resulting molded body from the mold; a step of washing the molded body removed from the mold; A step of drying the molded body after washing; having The step of washing the molded body includes immersing the molded body in a mixed solution of methanol and water. Effect of the Invention

[0009] According to one aspect of the present invention, it is possible to optimize cleaning of microneedles after removal from a mold while ensuring safety in living organisms. [Brief description of the drawings]

[0010] [Figure 1] FIG. 1 is a side view of a microneedle according to one embodiment of the present invention. [Diagram 2] FIG. 1 is a cross-sectional view of one form of microneedle having a reservoir. [Diagram 3] FIG. 2 is a cross-sectional view of one form of a mold used to manufacture the microneedle shown in FIG. [Figure 4] 1 is a graph showing the cleaning effect of a molded body in an example. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] <Microneedle> First, the microneedle will be described. Referring to FIG. 1, a microneedle 10 according to an embodiment of the present invention is shown, which has a base portion 100 and a plurality of needles 110 and is provided as a patch to be attached to the skin. The base portion 100 is a sheet-like portion that supports the plurality of needles 110. The plurality of needles 110 are supported by the base portion 100, and are configured as a needle array. The needles 110 are portions that are pierced into the skin when the microneedle 10 is used, and have sharp tips. The base portion 100 and the needles 110 may be made of different materials or may be made of the same material. When the base portion 100 and the needles 110 are made of the same material, they can be made at the same time. At least the needles 110 are hydrophilic, and before use of the microneedle 10, the drug is permeated into the needles 110, thereby carrying the drug therein. The needle 110 has a high mechanical strength sufficient to pierce the skin before piercing the skin, and has a property of absorbing water and releasing a drug immediately after piercing the skin. In this specification, the microneedle is also referred to as a "drug delivery microneedle."

[0012] [Base part] The base portion 100 can be made of various materials as long as the materials have the necessary mechanical strength so that the needles 110 can be well pierced into the skin against the elasticity of the skin when the needles 110 are pierced into the skin. Examples of such materials include polymer materials, ceramic materials having a porous structure, and metal materials. The base portion 100 is preferably made of a material having biocompatibility. In one embodiment, the base portion is preferably flexible enough to be deformed along the skin.

[0013] The base portion 100 can have a reservoir of a drug to be released from the needle 110. By having a reservoir, the drug can be released over a long period of time (for example, 7 days). A microneedle capable of releasing a drug over a long period of time can be suitably used as an insulin delivery microneedle that administers insulin as a drug according to blood glucose concentration.

[0014] The reservoir can be formed, for example, by forming the base part 100 into a concave (cup-shaped) shape with an open upper surface. Alternatively, the base part 100 can be formed from the same material as the needle 110, and the base part 100 itself, which is permeated with a drug, can be used as the reservoir. In this case, the base part 100 and the multiple needles 110 can be formed simultaneously by integral molding. In either case, the base part 100 is preferably made of a material that does not impede the continuity of drug flow from the needle 110 to the base part 100. The structure of a microneedle having a reservoir will be described in detail later.

[0015] The planar shape of the base portion 100 may be any shape, such as a circle, an ellipse, or a polygon, and may be, for example, a rectangle.

[0016] [needle] The length of the needle 110 is not limited as long as the needle 110 has a sufficient length to reach the stratum corneum when the needle 110 is punctured into the skin, and may be, for example, preferably 5 mm or less, more preferably 2 mm or less, and even more preferably 1 mm or less, and is preferably 100 μm or more, more preferably 500 μm or more, and even more preferably 1 mm or more in one embodiment. The number and arrangement of the needles 110 may be arbitrary. For example, a plurality of needles 110 can be arranged in a matrix of M×N (M and N are integers of 1 to 30). As an example of a specific arrangement, 10×12 needles 110 are arranged at a pitch of 500 μm in a rectangular area of ​​8 mm×8 mm. As another example of an arrangement, 11×11 needles 110 are arranged at a pitch of 1.2 mm in a circular area of ​​12 mm in diameter. The shape of the needle 110 may be arbitrary as long as it has a tip that can puncture the skin, and it can be preferably a pyramidal shape.

[0017] The needle 110 contains a gel composition capable of carrying and releasing a drug. In particular, when the microneedle 10 is a microneedle that delivers insulin as a drug, a sugar-responsive gel can be used as the gel composition. The sugar-responsive gel will be described later.

[0018] [Structure of microneedle with reservoir] As one aspect of this embodiment, one embodiment of the structure of a microneedle having a reservoir will be described with reference to FIG.

[0019] In the embodiment shown in FIG. 2, the base portion 100 is formed in a concave (cup-like) shape, and the open upper surface of the base portion 100 is sealed with a sheet 102 to form a space, thereby forming a reservoir 101. For example, a water-resistant adhesive 103 can be used to adhere the sheet 102. There is no particular limitation on the sheet 102, but from the viewpoint of water resistance and flexibility, for example, a silicone sheet having a thickness of 0.3 mm can be used. The drug can be filled into the reservoir 101 through the sheet 102 by syringe injection.

[0020] <Sugar-responsive gel> Next, the sugar-responsive gel will be described. The sugar-responsive gel (also referred to as "gel composition" or "gel") of this embodiment utilizes the mechanism by which a phenylboronic acid monomer changes its structure depending on the glucose concentration, as described below.

[0021] [ka]

[0022] Phenylboronic acid (PBA) dissociated in water reversibly binds to sugar molecules and maintains the above-mentioned equilibrium state. When the glucose concentration increases, glucose binds to the boronic acid and the gel expands in volume, but when the glucose concentration is low, the gel contracts. When the gel is filled in a drug delivery device, this reaction occurs at the gel interface in contact with blood, and the gel contracts only at the interface, resulting in a dehydration contraction layer that the inventors call the "skin layer." The insulin delivery device according to one embodiment of the present invention utilizes this property to control the release of insulin.

[0023] The sugar-responsive gel of this embodiment contains a polymerization reaction product of a mixture containing (A) a gelling agent, (B) a phenylboronic acid monomer, (C) a hydroxyl monomer, (D) a crosslinking agent, and (E) a photopolymerization initiator, and is a copolymer containing monomer units based on components (A) to (D). In this specification, the term "monomer unit" refers to a structural unit in a (co)polymer derived from a monomer, and the term "monomer" is sometimes used to mean "monomer unit".

[0024] Components (A) to (E) are described in detail below.

[0025] <(A) Gelling agent> The mixture used to prepare the sugar-responsive gel of this embodiment is (A) contains a gelling agent (also referred to as "component (A)") containing at least one selected from the group consisting of N-isopropyl methacrylamide (NIPMAAm), N-isopropylacrylamide (NIPAAm), N,N-dimethylacrylamide (DMAAm), and N,N-diethylacrylamide (DEAAm). The gelling agent forms the backbone of the sugar-responsive gel.

[0026] The gelling agent may be any biocompatible material that is biocompatible and capable of gelling, such as a biocompatible acrylamide compound (a compound having one acrylamide or methacrylamide group). The gelling agent preferably contains at least one compound selected from the group consisting of N-isopropylmethacrylamide (NIPMAAm), N-isopropylacrylamide (NIPAAm), N,N-dimethylacrylamide (DMAAm), and N,N-diethylacrylamide (DEAAm), and may contain two or more compounds.

[0027] The gelling agent (component (A)) can be contained at a ratio of, for example, 50 mol% or more, 60 mol% or more, 70 mol% or more, or 80 mol% or more, based on the total of components (A) to (E). The gelling agent can be contained at a ratio of, for example, 90 mol% or less, 80 mol% or less, 70 mol% or less, or 60 mol% or less, based on the total of components (A) to (E). In one embodiment, the concentration of the gelling agent based on the total of components (A) to (E) is preferably 50 mol% or more, more preferably 60 mol% or more, even more preferably 65 mol% or more, and is preferably 90 mol% or less, more preferably 80 mol% or less.

[0028] <(B) Phenylboronic acid monomer> The mixture used to prepare the sugar-responsive gel of this embodiment is The following general formula (1):

[0029] [ka] [In the formula, R is H or CH3, F is present independently, n is 1, 2, 3 or 4, and m is 0 or an integer of 1 or more.] The compound (B) contains a phenylboronic acid monomer represented by the formula (B):

[0030] The above-mentioned phenylboronic acid monomer has a fluorinated phenylboronic acid group in which hydrogen on the phenyl ring is replaced with 1 to 4 fluorines, and has a structure in which the carbon of the amide group is bonded to the phenyl ring. The phenylboronic acid monomer having the above structure has high hydrophilicity, and the pKa can be set to the biological level of 7.4 or less because the phenyl ring is fluorinated. Furthermore, this phenylboronic acid monomer not only acquires sugar recognition ability in a biological environment, but also becomes copolymerizable with the gelling agent of component (A), the hydroxyl monomer of component (C), and the crosslinking agent of component (D) due to the unsaturated bond, and can become a gel that undergoes a phase change depending on the glucose concentration.

[0031] In the phenylboronic acid monomer, when one hydrogen atom on the phenyl ring is replaced by fluorine atom, the introduction site of F and B(OH)2 may be any of ortho, meta, and para.

[0032] In general, a phenylboronic acid monomer in which m is 1 or more can have a lower pKa than a phenylboronic acid monomer in which m is 0. The upper limit of m is not particularly limited, but is, for example, 20 or less, preferably 10 or less, and more preferably 4 or less.

[0033] An example of the above phenylboronic acid monomer is a phenylboronic acid monomer in which R is hydrogen, n is 1, and m is 2, and this is 4-(2-acrylamidoethylcarbamoyl)-3-fluorophenylboronic acid (AmECFPBA), which is particularly preferred as a phenylboronic acid monomer.

[0034] The phenylboronic acid monomer represented by general formula (1) (component (B)) can be contained at a ratio of, for example, 5 mol% or more, 10 mol% or more, or 15 mol% or more, based on the total of components (A) to (E). Furthermore, the phenylboronic acid monomer represented by general formula (1) can be contained at a ratio of, for example, 35 mol% or less, 30 mol% or less, 25 mol% or less, or 20 mol% or less, based on the total of components (A) to (E). In one embodiment, the concentration of the phenylboronic acid monomer based on the total of components (A) to (E) is, for example, preferably 5 mol% or more, more preferably 10 mol% or more, and also preferably 30 mol% or less, more preferably 25 mol% or less.

[0035] <(C) Hydroxyl monomer> The mixture used to prepare the sugar-responsive gel of this embodiment is (C) the following general formula (2):

[0036] [ka] [In the formula, R 1 is H or CH3, m is an integer of 0 or 1 or more, R 2 is OH, saturated or unsaturated C substituted with one or more hydroxyl groups 1-6 Alkyl groups, saturated or unsaturated C substituted with one or more hydroxyl groups 3-10 C containing 1 to 4 heteroatoms selected from cycloalkyl groups, NH substituted with one or more hydroxyl groups, O, and S 3-12 Heterocyclic groups, C substituted with one or more hydroxyl groups 6-12 an aryl group, a monosaccharide group, or a polysaccharide group. The hydroxyl monomer ("component (C)", also simply referred to as "hydroxyl monomer") represented by the formula: By using the hydroxyl monomer, it is possible to form a gel that has high resistance to temperature changes and can suppress the release of a large amount of the drug, particularly at low temperatures.

[0037] The monomer of the above general formula (2) has a hydroxyl group in the molecule. Without being bound by a particular theory, it is believed that this hydroxyl group enhances the hydrophilicity of the gel, offsets the hydrophobicity of the boronic acid, and acts on the boronic acid in the gel to prevent the gel from excessively swelling. The upper limit of m is not particularly limited, but is, for example, 20 or less, preferably 10 or less, and more preferably 4 or less.

[0038] An example of the hydroxyl monomer is R 1 is hydrogen, m is 1, and R 2 Examples of monomers in which R is OH include N-hydroxyethyl acrylamide (NHEAAm), which is particularly preferred as a hydroxyl monomer. In particular, by using ethyl instead of methyl as the side chain, the rotational freedom of the side chain is increased, and the efficiency of the intermolecular crosslinking reaction (with the boronic acid side chain) is significantly improved. Therefore, by using NHEAAm, it is possible to obtain an optimal gel that undergoes a phase change depending on the glucose concentration. Note that, as an example of another hydroxyl monomer, R 2 may be, for example, a sugar derivative such as a catechol group or a glycolyl group. The monosaccharide may be, for example, glucose.

[0039] The hydroxyl monomer represented by the general formula (2) (component (C)) can be contained at a ratio of, for example, 8 mol% or more, 10 mol% or more, 12 mol% or more, 13 mol% or more, or 15 mol% or more relative to the total of the components (A) to (E). The concentration of the hydroxyl monomer represented by the general formula (2) (component (C)) relative to the total of the components (A) to (E) can be, for example, 21 mol% or less, 20 mol% or less, 18 mol% or less, 17 mol% or less, 16 mol% or less, 15 mol% or less, or 14 mol% or less. The concentration range can be specified by any combination of the upper and lower limits above. A preferred concentration range of component (C) relative to the total of components (A) to (E) is, for example, preferably 11 mol% or more, more preferably 12 mol% or more, even more preferably 13 mol% or more, and preferably 20 mol% or less, more preferably 18 mol% or less, even more preferably 16 mol% or less, and even more preferably 15 mol% or less.

[0040] <(D) Crosslinking agent> The mixture used to prepare the sugar-responsive gel of this embodiment contains (D) a crosslinker (also referred to as "component (D)"). The crosslinker may be any substance that is biocompatible and capable of crosslinking monomers, and preferably includes a compound having at least two acrylamide or methacrylamide groups in the molecule. Examples of crosslinkers include N,N'-methylenebisacrylamide (MBAAm), ethylene glycol dimethacrylate (EGDMA), and N,N'-methylenebismethacrylamide (MBMAAm).

[0041] The crosslinking agent (component (D)) can be contained in an amount of, for example, 1 mol% or more, 1.5 mol% or more, 2 mol% or more, 2.3 mol% or more, or 2.5 mol% or more relative to the total of components (A) to (E). Also, component (D) can be contained in an amount of 5 mol% or less, 4.5 mol% or less, 4 mol% or less, 3.5 mol% or less, 3 mol% or less, or 2.5 mol% or less relative to the total of components (A) to (E). The concentration range is a combination of the above upper and lower limits.

[0042] <(E) Photopolymerization initiator> The mixture used to prepare the sugar-responsive gel of this embodiment contains (E) a photopolymerization initiator (also referred to as "component (E)"). The photopolymerization initiator generates radicals, acids, bases, etc. when irradiated with active light such as ultraviolet light, and can be appropriately selected depending on the type of monomer, etc., and it is preferable to use a photoradical polymerization initiator.

[0043] The photo-radical polymerization initiator is preferably one having sensitivity to ultraviolet light having a wavelength shorter than 405 nm, and from the viewpoint of being able to fully utilize the energy emitted from the light source and being excellent in productivity, it is preferable that the maximum absorption wavelength is 300 nm to 400 nm, and more preferably 300 nm to 380 nm. The photo-radical polymerization initiator is not particularly limited, but examples thereof include alkylphenone radical polymerization initiators, acylphosphine oxide radical polymerization initiators, and oxime ester radical polymerization initiators. These photo-polymerization initiators may be used alone or in combination of two or more.

[0044] Examples of alkylphenone-based photopolymerization initiators include 2,2-dimethoxy-1,2-diphenylethan-1-one (IGM Resins, Omnirad 651), 1-hydroxy-cyclohexyl-phenyl-ketone (IGM Resins, Omnirad 184), 2-hydroxy-2-methyl-1-phenyl-propan-1-one (IGM Resins, Omnirad 1173), 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propan-1-one, 2-hydroxy-1-{4-[4-(2-hydroxy-2-methyl-propionyl)-benzyl]phenyl}-2-methyl-propan-1-one (IGM Resins, Omnirad 127), 2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one (IGM Resins, Omnirad 127), and 2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one (IGM Resins, Omnirad 127). Resins, Omnirad 907), 2-benzyl-2-dimethylamino-1-(4-morpholinophenyl)-butanone-1, 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(4-morpholinyl)phenyl]-1-butanone (IGM Resins, Omnirad 379EG), and the like.

[0045] Examples of the acylphosphine oxide photopolymerization initiator include 2,4,6-trimethylbenzoyl-diphenyl-phosphine oxide (IGM Resins, Omnirad TPO H) and bis(2,4,6-trimethylbenzoyl)-phenylphosphine oxide (IGM Resins, Omnirad 819).

[0046] Examples of the oxime ester radical polymerization initiator include 1-[4-(phenylthio)phenyl]-1,2-octanedione-2-(O-benzoyloxime) (product name: OmniradOXE-01, manufactured by IGM Resins).

[0047] The content of the photopolymerization initiator (component (E)) is not particularly limited, but is, for example, preferably 1 mol% or more, more preferably 2 mol% or more, and also preferably 11 mol% or less, more preferably 5 mol% or less, based on the total of components (A) to (E). When the polymerization reaction is carried out in a solvent, the concentration of the photopolymerization initiator is, for example, preferably 1.3 (w / v)% or more, more preferably 1.6 (w / v)% or more, even more preferably 3.2 (w / v)% or more, and also preferably 15.0 (w / v)% or less, more preferably 10 (w / v)% or less, and even more preferably 7 (w / v)% or less. If the content of the photopolymerization initiator is too low, polymerization may be insufficient. On the other hand, if the content of the photopolymerization initiator is too high, the gel may become non-uniform and brittle.

[0048] A preferred embodiment of the sugar-responsive gel is, for example, a polymer of a mixture in which N-isopropyl methacrylamide (NIPMAAm) as a gelling agent (main chain), 4-(2-acrylamidoethylcarbamoyl)-3-fluorophenylboronic acid (AmECFPBA) as a phenylboronic acid monomer, N-hydroxyethylacrylamide (HEAAm) as a hydroxyl monomer, N,N'-methylenebisacrylamide (MBAAm) as a crosslinking agent, and 2,2-dimethoxy-1,2-diphenylethan-1-one as a photopolymerization initiator are mixed in a predetermined molar ratio. A more preferred embodiment of the sugar-responsive gel of this embodiment is, for example, a polymer of a mixture in which the molar ratio of (NIPMAAm / AmECFPBA / HEAAm / MBAAm / 2,2-dimethoxy-1,2-diphenylethan-1-one) is adjusted to 65-70 / 10-15 / 10-15 / 1-5 / 1-5. As an example, it is preferable to adjust it to 68.66 / 12.11 / 13.46 / 2.8 / 2.94.

[0049] The inventors of the present invention have studied in detail the composition of the sugar-responsive gel produced by photopolymerization. As a result, they have found that by setting the molar ratio of (the sum of components (A) and (B)):component (C) within a predetermined range and setting the concentration of the crosslinker of component (D) within a predetermined range (i.e., setting the crosslink density within a predetermined range), a gel can be obtained that is accurate in response to changes in sugar concentration even when there is a temperature change, and is excellent in suppressing drug release (leakage) when the sugar concentration is below the normal value. Normally, the body temperature of mammals, including humans, is kept almost constant, but for example, when starting treatment with a drug delivery device, the patient's body temperature may temporarily drop after anesthetizing the patient or immediately after the drug delivery device is attached to the patient's body. Even in such cases, the sugar-responsive gel of this embodiment is accurate in response to changes in sugar concentration and is excellent in suppressing drug release (leakage) when the sugar concentration is below the normal value.

[0050] In the mixture for preparing the sugar-responsive gel of this embodiment, the molar ratio (the total of the gelling agent of component (A) and the phenylboronic acid monomer of component (B)) of the hydroxyl monomer of component (C) (also referred to as the "molar ratio of (A+B):C") is preferably 4.5:1 to 6.5:1, more preferably 4.8:1 to 6.3:1, even more preferably 5.0:1 to 6.3:1, and even more preferably 5.5:1 to 6.3:1. If the total amount of components (A) and (B) is too small compared to the amount of component (C), the drug may be released even when the glucose concentration is below the normal value, or the drug may not respond accurately to changes in the glucose concentration. If the total amount of components (A) and (B) is too large compared to the amount of component (C), the drug may not be released easily when the glucose concentration is high.

[0051] In the mixture for preparing the sugar-responsive gel of this embodiment, the ratio of the crosslinker of component (D) to the total of 100 mol% of components (A), (B), and (C) (also referred to as "crosslink density") is preferably 1.5 mol% or more, more preferably 2.0 mol% or more, even more preferably 2.5 mol% or more, even more preferably 2.8 mol% or more, and is preferably 4 mol% or less, more preferably 3.5 mol% or less. If the crosslink density is too small, the gel may have poor moldability and strength, while if the crosslink density is too large, the drug release amount may be insufficient. In addition, by setting the crosslink density within the above range, the gel can respond more accurately to changes in sugar concentration.

[0052] The sugar-responsive gel may contain other components such as silk fibroin and polyglycerol, if necessary, or may form a complex with other components.

[0053] In one embodiment, the total content of components (A) to (E) in the total amount (100% by mass) of the mixture used to prepare the sugar-responsive gel is preferably 90% by mass or more, more preferably 95% by mass or more, and may be 100% by mass.

[0054] <Method for preparing sugar-responsive gel> The gel can be prepared by mixing the above components (A) to (E) and copolymerizing the monomers by a photopolymerization reaction. The order and means of mixing the components are not particularly limited. The components are preferably mixed in a solvent. Any solvent that dissolves the monomers can be used as the solvent. Examples of such solvents include water, alcohol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), tetrahydrofuran (THF), ionic liquids, and combinations of two or more of these. Among these, for example, aqueous methanol solution and 2-methoxyethanol can be preferably used as the solvent, and 2-methoxyethanol is particularly preferred. When preparing the gel using a solvent, although there is no particular limitation, the total monomer concentration of components (A), (B), (C), and (D) in the solution is preferably 1 to 10 M, more preferably 3 to 8 M. In this specification, the unit "M" means "mol / L". As a mixing means, for example, a known device such as an ultrasonic dispersion device can be used. The temperature during mixing is not particularly limited, and may be, for example, room temperature (preferably 5 to 40°C, more preferably 10 to 35°C). In one embodiment, a monomer solution obtained by mixing components (A) to (D) may be prepared, and component (E) may be added thereto immediately before the polymerization reaction to form a pregel solution. In another embodiment, two or more monomer solutions having different compositions may be prepared, and mixed to obtain a desired composition, to which component (E) may be added.

[0055] The sugar-responsive gel of this embodiment is obtained by irradiating a pre-gel solution containing components (A) to (E) with light to polymerize the monomers. Specific examples of the light to be irradiated include one or more types of light selected from the group consisting of visible light, ultraviolet light, infrared light, X-rays, α-rays, β-rays, and γ-rays, and active electron beams. Among them, ultraviolet light is preferred because it is easy to control the progress of the polymerization reaction and a photopolymerization device that is widely used can be used. Examples of light sources include low-pressure mercury lamps, medium-pressure mercury lamps, high-pressure mercury lamps, ultra-high-pressure mercury lamps, xenon lamps, halogen lamps, carbon arc lamps, tungsten lamps, gallium lamps, excimer lasers, LED light sources, chemical lamps, black light lamps, microwave-excited mercury lamps, and metal halide lamps.

[0056] When the photopolymerization reaction is carried out with ultraviolet light, the ultraviolet irradiation intensity is not particularly limited, but is preferably 10 to 3,000 mW / cm. 2 , more preferably 10 to 1000 mW / cm 2 , and more preferably 10 to 500 mW / cm 2 The ultraviolet irradiation intensity is preferably an intensity in a wavelength region effective for activating a photopolymerization initiator. The time for irradiating light is preferably 0.1 seconds to 10 minutes, more preferably 0.1 seconds to 5 minutes, and further preferably 0.1 seconds to 3 minutes. When irradiating once or multiple times with such ultraviolet irradiation intensity, the integrated light amount is preferably 10 to 3,000 mJ / cm. 2 , more preferably 50 to 2,000 mJ / cm 2 , and more preferably 100 to 1,000 mJ / cm 2 It is.

[0057] [Microneedle manufacturing] The microneedle 10 can be manufactured by using a micromolding technique using a mold. In the micromolding technique, the needle 110 can be formed integrally with the base portion 100, so it is preferable to use a mold 200 having a cavity (recess) 201 formed in a shape combining the needle and the base portion, as shown in FIG. 3. As a material for forming the mold 200, for example, a silicone material such as polydimethylsiloxane (PDMS) can be used. In this embodiment, the material for forming the mold 200 is preferably a material that can transmit light for photopolymerizing the monomer in the pregel solution.

[0058] By using such a mold 200, the base part 100 and the needle 110 can be formed in one step. However, when the material constituting the base part 100 and the material constituting the needle 110 are different, first, a solution (pre-gel solution) in which the material constituting the needle 110 is dissolved in a solvent is poured into the part of the mold 200 corresponding to the needle 110, and the monomer of the pre-gel solution is polymerized in the mold 200 by light irradiation, and this is dried (the solvent is removed) to form the needle 110. Pouring and drying of the solution can also be performed multiple times. Next, a solution in which the material constituting the base part 100 is dissolved in a solvent is poured into the mold 200 and dried. The obtained molded body is removed from the mold 200. As a result, a microneedle 10 in which the base part 100 and the needle 110 are molded integrally can be obtained.

[0059] In another embodiment, a solution (pre-gel solution) in which a monomer mixture containing a monomer constituting the needle 110 is dissolved in a solvent is poured (injected) into a cavity 201 corresponding to the needle 110 of the microneedle mold 200. The amount of solution poured into the microneedle mold 200 is an amount that fills at least the cavity 201 corresponding to the needle 110 with the solution. Next, a sheet corresponding to the base part 100 is inserted into the microneedle mold 200 from above the poured solution. For example, a PE (polyethylene) sheet can be used as the sheet corresponding to the base part 100, and a porous PE sheet may be used. A porous body is inserted into the microneedle mold 200 so that the liquid surface of the solution contacts the porous body at the part where the solution and the PE sheet face each other. Alternatively, a PE sheet having a gel layer of the same composition as the needle 110 may be prepared, and the PE sheet may be arranged so that the gel layer part on the PE sheet contacts the solution in the part corresponding to the needle 110.

[0060] Since the needle 110 has a very fine structure, it is important to fill the solution up to the tip of the needle 110 when forming the needle 110. Therefore, after filling the needle 110 with the solution, a centrifugation process, a vacuum process, or a degassing process may be performed.

[0061] As described above, the sugar-responsive gel constituting the microneedle of this embodiment is formed by a photopolymerization reaction of the components (A) to (E). In one embodiment, the solution (containing a monomer mixture) poured into the needle 110 or into the mold of the base part 100 and the needle 110 is degassed, and then the monomer mixture is polymerized by light irradiation. The method of light irradiation is as described in the above-mentioned method for preparing the gel. The direction of light irradiation is not particularly limited, but it is preferable to irradiate from the tip direction of the needle, for example.

[0062] The molded body (microneedle 10) removed from the mold 200 contains unreacted monomers and polymers that have not been polymerized in its original state. Therefore, after the molded body is removed from the mold 200, the removed molded body is washed. A mixed solution of methanol and water is used as a washing liquid for washing. The washing liquid preferably has a methanol concentration of 40% by volume to 70% by volume. The higher the methanol concentration, the more the gel composition swells and the more efficiently the washing proceeds. However, if the methanol concentration is too high, the gel composition is significantly deformed due to swelling, which increases the possibility that the desired needle shape cannot be obtained, and the risk of the gel composition cracking during drying increases. On the other hand, if the methanol concentration is too low, the washing efficiency decreases.

[0063] The cleaning can be performed, for example, by placing the molded body in a suitable container containing the cleaning liquid. Although it is not essential to replace the cleaning liquid during cleaning, it is preferable to replace the cleaning liquid. By replacing the cleaning liquid, the molded body comes into contact with fresh cleaning liquid more frequently, which improves the cleaning efficiency and shortens the cleaning time. The cleaning liquid may be replaced once or multiple times (for example, 2, 3, 4, 5, 6, 7, 8, or 9 times). The immersion time of the molded body in the cleaning liquid (the time per time when the cleaning liquid is replaced) can be set arbitrarily within the range of 2 to 24 hours, and can be, for example, 2, 3, 5, 8, 10, 12, 18, or 24 hours. An excessively long immersion time leads to a decrease in the cleaning effect. The frequency of replacement of the cleaning liquid and the immersion time of the molded body in the cleaning liquid can be determined according to the methanol concentration of the cleaning liquid. When the methanol concentration is high, a small replacement frequency and immersion time are sufficient.

[0064] <Drug delivery devices> The present invention is not limited to the microneedle 10, but is applicable to a drug delivery device (also referred to as a "drug delivery device" or simply "device") containing a sugar-responsive gel. The drug delivery device is preferably used for delivering insulin. The drug delivery device may take any form, such as a body-implantable type, a microneedle type, a tablet type, or the like. For a body-implantable type device, for example, JP 2016-209372 A and International Publication Pamphlet WO2017 / 069282 can be referred to. The drug delivery device may also be implanted in the body as a gel tablet (see the Examples described below). The shape and size of the gel tablet are not particularly limited.

[0065] In a drug delivery device, a drug (e.g., insulin) may be preliminarily contained in the gel. To achieve this, the gel is immersed in an aqueous solution (e.g., phosphate buffer solution) containing a prescribed concentration of the drug, allowing the drug to diffuse into the gel. The gel is then removed from the aqueous solution and immersed in, for example, hydrochloric acid for a prescribed period of time, forming a thin dehydration shrink layer (called a skin layer) on the surface of the gel body, thereby encapsulating (loading) the drug and obtaining a gel that can be filled into the device.

[0066] In the sugar-responsive gel, a phenylboronic acid monomer and a hydroxyl monomer are copolymerized with a gelling agent and a crosslinking agent to form a gel body. A drug such as insulin is diffused into this gel, and the surface of the gel body can be surrounded by a dehydration shrinkage layer. As a result, under physiological conditions (e.g., pKa 7.4 or less, temperature 35°C to 40°C), when the glucose concentration increases, the gel expands and the dehydration shrinkage layer disappears, allowing the drug (e.g., insulin) in the gel to be released to the outside. On the other hand, when the glucose concentration decreases again, the expanded gel contracts and a dehydration shrinkage layer (skin layer) is formed again on the entire surface, preventing the drug (e.g., insulin) in the gel from being released to the outside. Therefore, the sugar-responsive gel used in the present invention can autonomously release a drug (e.g., insulin) in response to the glucose concentration.

[0067] <Drugs> Drugs that can be delivered using the sugar-responsive gel of this embodiment include, but are not limited to, proteins, peptides, nucleic acids, other high molecular weight polymers, low molecular weight compounds, etc. Drugs may be therapeutic agents for diseases, preventive drugs, vaccines, nutritional supplements, etc. A particularly preferred drug is insulin. Various natural insulins or modified insulins are available commercially or by synthesis. For example, Humulin (registered trademark) may be used as insulin. Humulin (registered trademark) is human (recombinant) insulin sold by Eli Lilly and Company. Various insulin preparations, including fast-acting, intermediate-acting, and sustained-acting, have been developed, and can be appropriately selected and used. EXAMPLES

[0068] The present invention will be specifically described with reference to the following examples, but the present invention is not limited to these examples.

[0069] <Preparation of pregel solution> The materials (monomers) used in preparing the monomer solution are as follows: (Gelling agent (main chain)) NIPAAm: N-isopropylacrylamide (Phenylboronic acid) AmECFPBA: 4-(2-acrylamidoethylcarbamoyl)-3-fluorophenylboronic acid (Hydroxyl Monomer) NHEAAm: N-Hydroxyethylacrylamide (Crosslinking agent) MBAAm: N,N'-methylenebisacrylamide

[0070] In this example, the total concentration of monomers other than the crosslinking agent (gelling agent, phenylboronic acid, and hydroxyl monomer) is 5M, and the crosslinking density is 3%, which is described as "5M3%". The same applies to other compositions. "Crosslinking density" refers to the molar concentration of the crosslinking agent relative to the total amount of the gelling agent, phenylboronic acid, and hydroxyl monomer.

[0071] <Preparation of monomer solution> As monomer solutions for producing a 5M3% gel, 5M3% monomer solution A (also referred to as "monomer solution A") and 5M3% monomer solution B (also referred to as "monomer solution B") were prepared. The reagents (monomers) were added to 2-methoxyethanol as a solvent and dissolved by ultrasonic irradiation at room temperature for 5 minutes to obtain the following concentrations, to prepare monomer solution A and monomer solution B. The resulting monomer solutions A and B were stored in a refrigerator.

[0072] <Crosslink density: 3%, 5M3% monomer solution A> (Crosslinking agent) MBAAm: 5M x 0.03 x 154.17 = 23.12 mg / mL (Gelling agent) NIPAAm: 5M x 0.85 x 113.16 = 480.93 mg / mL (Phenylboronic acid monomer) AmECFPBA: 5M x 0.15 x 280 = 210mg / mL

[0073] <Crosslink density: 3%, 5M3% monomer solution B> (Crosslinking agent) MBAAm: 5M x 0.03 x 154.17 = 23.12 mg / mL (Hydroxyl monomer) NHEAAm: 5M x 115.13 = 575.65mg / mL

[0074] When preparing the microneedle, the above-mentioned monomer solution A and monomer solution B were mixed with a vortex to obtain a mixing ratio (volume ratio) of monomer solution A:monomer solution B = 6:1, and 40 mg of a photopolymerization initiator (Irgacure 651 (Omnirad 651), manufactured by BASF Japan) was added to 1 mL of the mixed solution, and the solution was completely dissolved by ultrasonication for 10 minutes to produce a pregel solution. The mixing ratio of monomer solution A to monomer solution B corresponds to the molar ratio of {(NIPAAm + AmECFPBA): NHEAAm}, that is, {(gelling agent + phenylboronic acid monomer): hydroxyl monomer}. The concentration of the crosslinker (crosslink density) represents the ratio (mol) of MBAAm to the total of AmECFPBA, NIPAAm, and NHEAAm in the mixed monomer solution.

[0075] <Preparation of microneedles> (Preparation of PE plate with gel layer) A PE (polyethylene) plate with a thickness of 2 mm and a diameter of 11 mm was gently placed on top of 165 μL of pre-gel solution poured into a concave mold with a depth of 0.5 mm, a circular bottom with a diameter of Φ = 11 mm, and an open top, and immediately exposed to UV irradiation (wavelength 365 nm, 150 mW / cm 2 After heating at 400° C. for 30 seconds, the plate was air-dried overnight to prepare a PE plate with a gel layer. The PE plate with the gel layer corresponds to the base of the microneedle.

[0076] (Microneedle molding) 125 μL of the pre-gel solution kept at 50°C was poured into the cavity corresponding to the needle of a silicone (polydimethylsiloxane (PDMS)) microneedle mold that had been pre-warmed to 50°C, and the pressure was reduced using a water flow pump to remove air bubbles. This operation was repeated twice. Next, the PE plate with the gel layer prepared above (the PE plate prepared using the pre-gel solution) was gently inserted, and UV irradiation (wavelength 365 nm, 150 mW / cm) was applied from the needle tip side. 2 The monomer was polymerized and the pre-gel solution in the mold was gelled. After a few minutes of irradiation, when the mold had cooled to room temperature, the microneedle gel was gently removed from the mold and air-dried at room temperature overnight to obtain a molded body in which the PE plate and needles were integrated.

[0077] (Cleaning of microneedles) The molded body (microneedle) removed from the mold 200 was washed. The washing was performed as follows. First, the molded body was placed in a container filled with the washing liquid while being immersed in the washing liquid, and left to stand at room temperature for 50 hours. A mixed solution of methanol and water (methanol concentration=60% by volume) was used as the washing liquid. During this standing period, the washing liquid was replaced 2 hours and 26 hours after the start of immersion of the molded body.

[0078] The molded body was then further immersed in the cleaning solution at room temperature until the pH of the cleaning solution reached 6 or more. The pH was measured by the glass electrode method. A pH meter F-5(2) and a pH electrode 9618S-10D manufactured by Horiba, Ltd. were used for the measurement. The same mixed solution of methanol and water (methanol concentration = 60% by volume) as above was used as the cleaning solution. The cleaning solution was appropriately changed during this immersion period.

[0079] When the pH of the washing solution reached 6 or more, the mixed solution of methanol and water was replaced with pure water, and the molded body was immersed in the pure water at room temperature for 24 hours or more. After that, the molded body was taken out of the pure water and naturally dried to obtain a microneedle.

[0080] (Confirmation of cleaning effect) From the viewpoint of confirming safety to living organisms, the cleaning effect was confirmed by the following procedure.

[0081] In the above-mentioned washing process, the mixed solution was collected every time the mixed solution of methanol and water, which was the washing liquid, was replaced. The collected mixed solution was concentrated using an evaporator and dissolved in deuterated methanol. Then, the substances contained in the mixed solution were analyzed using a nuclear magnetic resonance analyzer (AVANCE III 400 manufactured by Bruker).

[0082] As a result of the analysis, it was confirmed that the concentrations of unreacted monomers and unpolymerized polymers significantly decreased two days after the start of cleaning, as shown in Figure 4.

[0083] Regarding safety in living organisms, the US Food and Drug Administration (FDA) standard states that the bioacceptable limit for acrylamide is 0.36μg / kg body weight / day, which translates to 25.2μg / day for a body weight of 70kg. This confirmed that the safety limit was reached on the third day after the start of washing. Acrylamide has also been cited as a problem for its neurotoxicity and carcinogenicity, but it is recommended that the acceptable limit for preventing neurotoxicity be 40μg / kg body weight / day or less, and for carcinogenicity, it is 2.6μg / kg body weight / day or less, and it was confirmed that the deviation from these limits was within the acceptable range.

[0084] Although preferred embodiments of the present invention are shown herein, it will be apparent to those skilled in the art that such embodiments are provided for illustrative purposes only, and that various modifications, changes, and substitutions may be made by those skilled in the art without departing from the present invention. It should be understood that various alternative embodiments of the invention described herein may be used in practicing the present invention. In addition, the contents of all publications, including patents and patent applications, referenced in this specification should be construed as being incorporated by reference as if set forth herein. [Explanation of symbols]

[0085] 10 Microneedle 100 Base 101 Reservoir 110 Needle 200 Series 201 Cavity

Claims

1. A method for producing a microneedle, comprising: A step of preparing a mold in which a cavity corresponding to the base portion and the needle portion of the microneedle having a base portion and at least one needle portion integrally provided on the base portion is formed; preparing a pre-gel solution comprising a monomer mixture; injecting the pre-gel solution into at least a portion of the cavity of the mold corresponding to the needle; polymerizing the monomer mixture in the pre-gel solution in the mold to form a gel composition; removing the resulting molded body from the mold; a step of washing the molded body removed from the mold; A step of drying the molded body after washing; having The method for manufacturing a microneedle, wherein the step of washing the molded body includes immersing the molded body in a mixed solution of methanol and water.

2. The method for producing a microneedle according to claim 1, wherein the mixed solution has a methanol concentration of 30% by volume to 70% by volume.

3. The method for producing a microneedle according to claim 1 , wherein the step of washing the molded body includes replacing the mixed solution one or more times.

4. The method for producing a microneedle according to claim 3, wherein the immersion time of the molded body in the mixed solution for each exchange is 2 hours to 24 hours.

5. The method for producing a microneedle according to claim 1 , wherein the monomer mixture comprises a gelling agent, a phenylboronic acid-based monomer, a hydroxyl-based monomer and a crosslinking agent.

6. The monomer mixture further comprises a photopolymerization initiator, The method for producing a microneedle according to claim 5 , wherein the step of forming the gel composition includes polymerizing the monomer mixture by light irradiation.

Citation Information

Patent Citations

  • Glucose reactive composite gel composition, method for producing same, insulin delivery microneedle including said glucose reactive composite gel composition, and producing method therefor

    WO2019182099A1